HilleVax logo

HilleVaxNASDAQ: HLVX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

29 April 2022

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$90.11 M
-90%vs. 3y high
42%vs. sector
-vs. 3y high
-vs. sector
-87%vs. 3y high
27%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 01 Nov 2024 23:07:14 GMT
$1.81-$0.03(-1.63%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

HLVX Latest News

What Makes HilleVax (HLVX) a New Buy Stock
zacks.com14 October 2024 Sentiment: POSITIVE

HilleVax (HLVX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

HilleVax, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by HilleVax (HLVX)
accesswire.com29 August 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / August 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.

Levi & Korsinsky Investigates Possible Securities Fraud Violations by HilleVax, Inc. (HLVX)
accesswire.com28 August 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / August 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.

Investors who lost money on HilleVax, Inc. should contact Levi & Korsinsky about an ongoing investigation - HLVX
accesswire.com27 August 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / August 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.

HilleVax, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HLVX
accesswire.com26 August 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / August 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.

ATTENTION HLVX SHAREHOLDERS: Investors who Lost Money on HilleVax, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
accesswire.com23 August 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / August 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.

ATTENTION HLVX SHAREHOLDERS: Investors who Lost Money on HilleVax, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
accesswire.com22 August 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.

HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
globenewswire.com08 August 2024 Sentiment: NEUTRAL

$245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is exploring the potential for continued development of its HIL-214 and HIL-216 norovirus vaccine candidates in adults BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended June 30, 2024 and highlighted recent progress. Recent Business Highlights In Q3 2024, HilleVax announced that the NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints and that the company would discontinue further development of HIL-214 in infants.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
globenewswire.com03 August 2024 Sentiment: NEGATIVE

NEW YORK, Aug. 03, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  HilleVax, Inc. (“HilleVax” or the “Company”) (NASDAQ: HLVX).   Such investors are advised to contact Danielle Peyton at [email protected]  or 646-581-9980, ext. 7980.

Stakeholders Of Hillevax Inc Are Encouraged By The Schall Law Firm To Join The Alleged Securities Fraud Investigation
accesswire.com26 July 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

What type of business is HilleVax?

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

What sector is HilleVax in?

HilleVax is in the Healthcare sector

What industry is HilleVax in?

HilleVax is in the Biotechnology industry

What country is HilleVax from?

HilleVax is headquartered in United States

When did HilleVax go public?

HilleVax initial public offering (IPO) was on 29 April 2022

What is HilleVax website?

https://www.hillevax.com

Is HilleVax in the S&P 500?

No, HilleVax is not included in the S&P 500 index

Is HilleVax in the NASDAQ 100?

No, HilleVax is not included in the NASDAQ 100 index

Is HilleVax in the Dow Jones?

No, HilleVax is not included in the Dow Jones index

When was HilleVax the previous earnings report?

No data

When does HilleVax earnings report?

The next expected earnings date for HilleVax is 08 November 2024